Live Price
Live Volume
Chart Volume 0
Volume 0
5 secScribe Therapeutics Market Segments
Premarket
+0.70(+2.32%)
| Open | $30.17 |
|---|---|
| Close | $30.87 |
| Low | $29.75 |
| Low Change | -0.42 (-1.39%) |
| High | $30.87 |
| High Change | +0.70 (+2.32%) |
| Range | $1.12 |
| Volume | 2.092K |
| Dollar Volume | $64.58K |
Overnight
*No Trades in Segment
After Hours Yesterday
+0.73(+2.48%)
| Open | $29.42 |
|---|---|
| Close | $30.15 |
| Low | $29.42 |
| Low Change | 0.00 (0.00%) |
| High | $30.15 |
| High Change | +0.73 (+2.48%) |
| Range | $0.73 |
| Volume | 14.951K |
| Dollar Volume | $450.77K |
Regular Trading Hours Yesterday
-0.49(-1.63%)
| Open | $29.97 |
|---|---|
| Close | $29.48 |
| Low | $28.55 |
| Low Change | -1.42 (-4.74%) |
| High | $30.53 |
| High Change | +0.56 (+1.85%) |
| Range | $1.98 |
| Volume | 111.152K |
| Dollar Volume | $3.28M |
Premarket Yesterday
*No Trades in Segment
Scribe Therapeutics News
There is no current news for this stock at the moment.
Scribe Therapeutics Top Trades
Scribe Therapeutics's top trade so far today returned +3.76%, while the top short trade returned -1.39%.
Scribe Therapeutics Moving Averages
| 5 Day Moving Average (SMA5) | $30.05 |
|---|---|
| 10 Day Moving Average (SMA10) | $30.04 |
| 20 Day Moving Average (SMA20) | $30.19 |
| 50 Day Moving Average (SMA50) | — |
| 100 Day Moving Average (SMA100) | — |
| 200 Day Moving Average (SMA200) | — |
Scribe Therapeutics Statistics
| Average Volume (30 Days) | — |
|---|---|
| P/E Ratio (Current) | — |
| EPS (Current) | — |
| Dividend Yield | — |
| Free Cash Flow | — |
| Cash Ratio | — |
| Current Ratio | — |
| Quick Ratio | — |
| Debt to Equity | — |
| Enterprise Value | — |
| EV to EBITDA | — |
| EV to Sales | — |
| Price to Book | — |
| Price to Cash Flow | — |
| Price to Free Cash Flow | — |
| Price to Sales | — |
| Return on Assets | — |
| Return on Equity | — |
Scribe Therapeutics Stock Splits
There have been no stock splits for Scribe Therapeutics (SCTX).
Scribe Therapeutics Dividends
There have been no dividends for Scribe Therapeutics (SCTX).